Anika Therapeutics, Inc.
ANIK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | -1.4% | 7.8% | 2,128.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | -$0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 56% | 50.9% | 56.1% | -1,749.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | -$0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -11.6% | -14.8% | -16.4% | -2,156.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.4% | -14.1% | -18.6% | 1,695% |
| EPS | -0.16 | -0.28 | -0.34 | -1.5 |
| % Growth | 42.9% | 17.6% | 77.3% | – |
| EPS Diluted | -0.16 | -0.28 | -0.34 | -1.5 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | – | $0 |
| Interest Expense | $0 | $0 | – | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -3% | -9.8% | -10.3% | -2,056.5% |